The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AXSM | +30.67% | +152.35% | +20.34% | +1,777% |
| S&P | +16.53% | +80.89% | +12.59% | +228% |
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
The biotech is slowly rising in prominence.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $196.00M | 65.0% |
| Gross Profit | $181.40M | 70.8% |
| Gross Margin | 92.55% | 3.1% |
| Market Cap | $9.21B | 124.5% |
| Market Cap / Employee | $9.95M | 0.0% |
| Employees | 925 | 35.4% |
| Net Income | -$28,559.00K | 61.9% |
| EBITDA | -$33,751.00K | 43.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $322.93M | 2.4% |
| Accounts Receivable | $224.46M | 58.1% |
| Inventory | 27.9 | 77.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $145.13M | -23.5% |
| Short Term Debt | $72.98M | 452.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.11% | 20.5% |
| Return On Invested Capital | -107.32% | -16.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18,724.00K | 28.6% |
| Operating Free Cash Flow | -$18,653.00K | 28.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 99.55 | 96.57 | 82.79 | 124.62 | 182.50% |
| Price to Sales | 13.19 | 10.43 | 10.82 | 14.48 | 36.01% |
| Price to Tangible Book Value | -2954.76 | -1235.33 | 349.71 | 469.77 | 270.88% |
| Enterprise Value to EBITDA | -105.18 | -119.04 | -195.60 | -270.88 | 303.87% |
| Return on Equity | -282.2% | -280.7% | -275.5% | -252.1% | 8.84% |
| Total Debt | $211.23M | $223.39M | $218.60M | $218.11M | 7.49% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
